Medicinal Products for Human Use - UNITED KINGDOM

Competent authority

Contact Details	**Contact Name 1** MHRA - Medicines and Healthcare products Regulatory Agency **Phone** +44 (0) 20 3080 6000 **Email General** info@mhra.gsi.gov.uk **Address** 151 Buckingham Palace Road, Victoria **ZIP/City** London SW1W 9SZ **Country** United Kingdom (UK) **Web address** https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency **Additional Information** MHRA is the competent authority for all counties in the UK.
Trial Authorisation / Registration / Notification	**Regulatory and ethics bodies involved in approval process** Competent Authority/-ies (CA) National Ethics Committee NHS R&D (Research & Development) Forum **CA - Submission for authorisation mandatory for** All clinical trials on Medicinal Products (MP) **CA - Registration/ notification without approval required for** – **CA - Submission required to** National CA **Additional Information** Use the MHRA’s online algorithm "Is it a clinical trial of a medicinal product?" to find out if your study needs MHRA authorization, available on the MHRA's website.
Submission of Application	**Responsible for study submission** Sponsor Legal representative domiciled in the EU/EEA **Entitled to study submission** –

	Prerequisites for submission – **Guidance on submission of application available** Yes **Guidance on submission of application** Clinical trials for medicines: apply for authorisation in the UK **National legal framework in place** Yes **Applicable national legal framework/ Reference** The procedure of the applications and the required documents are described in Part 3 of the Medicines for Human Use (Clinical Trials) Regulations 2004.
Submission Format	**Format option(s)** Online portal **Preferred format** – **Online portal** Integrated Research Application System (IRAS)
Language of Submission	**Language(s) of application** English **Preferred language of application** – **English accepted** – **Documents mandatory to be in official national language** –
Submission Fees	**Fees for trial submission mandatory** Yes **Fees** Application with an IMP dossier: 3400 GBP (approx. 4290 EURO) Application of substantial amendments: 250 GBP (approx. 315 EURO) No fee for Phase IV notifications **Waiver for academic (non-commercial) studies possible** Not specified **Official guidance on required fees available** Yes **Official guidance on required fees** The "Statutory guidance: Current MHRA fees" is available on the MHRA website.
Timelines Authorisation	**General timespan (max nr days)** 30

Mode of approval (General)

Explicit

ATMP/GMO trials (max nr days)

30

Mode of approval (ATMP/GMO trials)

Explicit

External expert advice required (max nr days)

+ 90

Xenogeneic cell therapy (max nr days)

Not specified

Mode of approval (Xenogeneic cell therapy)

–

Timespan counted from

Date of receipt of valid application

National legal framework in place

Yes

Applicable national legal framework/ Reference

Part 3, Section 18-20 of the Medicines for Human Use (Clinical Trials) Regulations 2004

Additional Information

Applications for healthy volunteer trials and sponsor-determined phase I trials in non-oncology patients may qualify for a shortened assessment time (average 14 days). You should state on your covering letter if you think your trial is eligible.

Amendments/ Substantial Amendments (SA)

Notification mandatory for

–

Authorisation mandatory for

Any substantial amendments

Responsible for submission of SA

Sponsor

Standard notification form available

Yes

Standard notification form

European Standard form: Substantial Amendment Notification Form
Submissions shall be made through the Common European Submission Platform (CESP).

Timeline for approval of SA (max nr days)

35
From date of receipt of valid application
By explicit (written) notification

Guidance on submission of SA available

Yes

Guidance on submission of SA

Detailed Guidance is available on the MHRA website: "Clinical trials for medicines: manage your authorisation, report safety issues - Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report"

National legal framework in place

Yes

Applicable national legal framework/ Reference

Part 3 sections 22-24 of the Medicines for Human Use (Clinical Trial) Regulations 2004

End of Trial

End of trial declaration mandatory for

All clinical trials requiring authorisation by CA

Responsible for End of trial declaration

Sponsor

Regular Termination - Declaration timespan (max nr days)

90

Timespan counted from

–

Early/premature Termination - Declaration timespan (max nr days)

15

Reasons for early termination shall be clearly stated

Yes

Standard Declaration form available

Yes

Standard Declaration form

A declaration of the end of a clinical trial should be sent to MHRA within 90 days of the global end of the trial.

European Standard Declaration Form (Eudralex Volume 10) to be used.
End of trial declarations shall be submitted via CESP.

Guidance on End of trial declaration available

Yes

Guidance on End of trial declaration

"Clinical trials for medicines: manage your authorisation, report safety issues - Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report"

National legal framework in place

Yes

Applicable national legal framework/ Reference

Part 3, section 27 and Schedule 3, Part 4 of the Medicines for Human Use (Clinical Trials) Regulations 2004

Ethics committee

Contact Details	**Contact Name 1** NHS- Health Research Authority (HRA) **Address** 80 London Road/ Skipton House **ZIP/City** London SE1 6LH **Country** United Kingdom (UK) **E-Mail** HRA.Queries@nhs.net **Web address** http://www.hra.nhs.uk **Additional Information** Further contact details and HRA Offices and Research Ethics Committee Centres are provided on HRA website.
Ethical Review – General	**Submission for Ethical review mandatory for** All clinical trials on Medicinal Products (MP) **Submission to CA and EC to be performed in the following order** In parallel Sequentially (in any order) **Regulatory and ethics bodies involved in approval process** Competent Authority/-ies (CA) National Ethics Committee NHS R&D (Research & Development) Forum

Study specific Requirements

Sponsor	**Sponsor - Definition available in national law** Yes **Sponsor - Definition (pursuant to national law)** The sponsor who is an individual, company or organisation takes responsibility for the initiation, management and/or financing (or arranging the financing) of a clinical trial (see Section 3 of the Clinical Trial Regulations 2004) **Sponsorship mandatory** Yes **Co-Sponsor - Definition available in national law** Yes **Co-Sponsor - Definition (pursuant to national law)** There is a peculiarity in the UK because co-sponsorship is allowed under UK law according to section 3 paragraph 2 of the Medicines for Human Use (Clinical Trials) Regulations 2004: "(2) If two or more persons take responsibility for the matters specified in paragraph (1) in relation to a clinical trial, those persons may— (a)take joint responsibility for carrying out the functions of the sponsor of that trial under these Regulations; or (b)allocate responsibility for carrying out the functions of the sponsor of that trial in accordance with paragraphs (4) to (10)."

	Co-sponsorship allowed Yes **Legal representative based in the EU/EEA is mandatory where Sponsor is located outside EU/EEA:** Yes
Investigator	**Entitled to be principal investigator** – **Additional Information** The investigator involved has various duties (e.g. in relation to SAE reporting and informed consent). Several tasks can be delegated by the sponsor to the investigator/coordinating investigator by contract (but not the legal responsibility).
Study Participants - Informed Consent (IC)	**Standard IC form (ICF) available** Not specified **IC is regulated by law** Yes **Informed Consent - Definition/ Requirements** Before starting a clinical trial the informed consent of the participant is required. **Applicable national legal framework/ Reference** Schedule 1, Part 1-5 of the Medicines for Human Use (Clinical Trials) Regulations 2004.
Study Participants - Vulnerable Population	**Minors / Children - Studies allowed** Yes Special provisions apply **Specific provision** The informed consent given by a person with parental responsibility or a legal guardian to a minor taking part in a clinical trial shall represent the minor’s presumed will. **Legal framework/Reference (Minors/Children)** Schedule 1, Part 4 of the Medicines for Human Use (Clinical Trials) Regulations 2004 **Incapacitated persons - Studies allowed** Yes Special provisions apply **Legal framework / Reference (Incapacitated persons)** Schedule 1, Part 5 of the Medicines for Human Use (Clinical Trials) Regulations 2004 **Emergency situations - Studies allowed** Yes Special provisions apply **Emergency situation without prior consent of patient or proxy - Studies allowed** No

Legal framework / Reference (Emergency Situation)

Schedule 1, Part 5 of the Medicines for Human Use (Clinical Trials) Regulations 2004

Pregnant or breastfeeding women - Studies allowed

Not specified

National legal framework for protection of vulnerable populations in place

Yes

Applicable legal framework / Reference (Vulnerable Population)

Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004

National legislation

Clinical Trials on IMPs in Humans	**Applicable national regulations** National Act on Medicinal Products **Transposition of (CT) Directive 2001/20/EC (or comparable national legal framework)** On 1 May 2004 the first Clinical Trials regulation came into force, followed by several amendments, implementing the Clinical Trials Directive 2001/20/EC and GCP Directive 2005/28/EC. - The Medicines for Human Use (Clinical Trials) Regulations 2004 - The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 - The Medicines for Human Use (Clinical Trials) Amendment (No.2) Regulations 2006 **Transposition of (GCP) Directive 2005/28/EC** Incorporated in transposition act(s) of Directive 2001/20/EC **Additional Information** Please note that in addition to the main amendments listed above, there have been several additional amendments to the original Statutory Instrument and the legislation is constantly evolving. For up to date comprehensive list of all relevant amendments please see MHRA.
Gene Therapy	**Specific requirements** Yes **Applicable legal framework** (1) The Medicines for Human Use (Clinical Trials) Regulations 2004 (2) The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (3) The Medicines for Human Use (Clinical Trials) Amendment (No.2) Regulations 2006 (4) The Medicines for Human Use (Advanced Therapy Medicinal Products and Miscellaneous Amendments) Regulations 2010 Due to the fact that gene therapy medicinal products are covered by the Medicines for Human Use Regulations 2004 the legal procedure is generally the same as for medicinal products for human use. Exceptions and peculiarities regarding CA and EC procedures are provided in part 3 section 13, 14, 15 and 19 of the Medicines for Human Use Regulations 2004. (5) As a matter of principle Good Manufacturing Practice (GMP) is required for the manufacture of medicinal products for human use. The EC-GMP-Guideline covers this issue.
Blood & Tissue Samples	**Specific requirements** Yes

Applicable legal framework

- The Human Tissue Act 2004,
- The Human Tissue (Scotland) Act 2006
must be considered In relation to the removal, storage and use of human organs and other tissues.